The combined treatment enhanced tumor growth inhibition in pancreatic cancer xenografts, suggesting that it might represent a new potential therapy for pancreatic cancers that co-express HER2 and HER3. This evidence concerns the gene ERBB3 and familial pancreatic carcinoma.